Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


The Fertility Show


 

Book Review: Ethical and Legal Requirements for Transnational Genetic Research

26 September 2011

By Professor Sandy Raeburn

Appeared in BioNews 626

Ethical and Legal Requirements of Transnational Genetic Research

By Dr Marian Arning, Professor Nikolaus Forgó, Professor Regine Kollek, Dr Tina Krügel and Dr Imme Petersen

Published by Hart Publishing

ISBN-10: 1849461287, ISBN-13: 978-1849461283

Buy this book from Amazon UK

'Ethical and Legal Requirements of Transnational Genetic Research' by Dr Marian Arning, Professor Nikolaus Forgó, Professor Regine Kollek, Dr Tina Krügel and Dr Imme Petersen


First, here is the bad news. Readers attracted by this title are in for a stormy and depressing journey. The writing, both in choice of language and sentence construction, is turgid. The problems of 'plain English' start in the six-page introduction, reach a low point in the ethical chapter and only improve slightly in the legal section.

The importance of international collaboration in research which follows up the Human Genome Project cannot be over-stated; worthwhile benefits could soon be realised. People from diverse communities differ in DNA and disease incidence; these differences give clues to the origin and functions of some genes. What a pity if unclear writing deters enthusiasts!

Let me set the scene. Two to three decades ago the chromosomal locations of genes were being mapped and mutation causing Mendelian (single gene) disorders were then delineated. In most communities the conditions were rare; samples from affected families were therefore collected from international sources. We asked permission from the affected families to take DNA samples and to carry out research 'to help to identify their disease gene'. We said that this work would not bring immediate benefit, but might explain the illness better: 'In the future there might be more options'. If research data indicated benefits for participating families, they would be informed. If they wished to explore possibilities (e.g. carrier or presymptomatic tests) they could ask for repeat testing in a service laboratory (i.e. one with validation and quality control procedures beyond those of research). If, later, samples might be used for other purposes we promised to contact them.

Life is more complex now. DNA studies often screen the whole genome for markers which are associated with complex genetic conditions, including cancer. Patients and other participants need to make informed choices about joining such studies and allowing their DNA data to be stored accessibly for future research. Studies often focus on common familial disorders and the approach is 'blunderbuss', i.e. across the whole genome; thus the findings may not only clarify specific risks, but those of which the subject was unaware. Dilemma! There are good reasons to review topics accurately and completely, to research ethically and to summarise the findings clearly.

The senior authors, Professors Forgo and Kollek, are from the Departments of Law and of Technology Assessment respectively of the University of Hamburg. The others are senior research fellows. Their research was funded with about €11 million from the European Commission 6th Framework and was entitled 'Advancing Clinico-Genomic Trials on cancer' (ACGT). The aim was 'to deliver to the cancer research community an integrated clinico-genomic information and communication technology (ICT) environment enabled by a powerful Grid infrastructure. ACGT's vision is to become a pan-European voluntary network or Grid connecting individuals and institutions to enable the sharing of data and tools'.

To do so, ACGT focussed on how to design experiments and avoid biases and errors, how to develop 'methods for heterogeneous...data source integration, including ontologies that facilitate mapping and information retrieval', how to select, check, 'clean' and pre-process genomic and medical data and how to incorporate collaborative approaches to data analysis. Perhaps you now understand my earlier comments about clarity?

Reading this book, you might think that this project involved no hands-on genetic researchers, no clinicians skilled in enabling patients to make informed decisions and no input from European patient organisations such as the Genetic Alliance! My thoughts wandered to the Greek philosophers who wished to find out how many teeth horses had, debating fiercely without opening the equine mouths and counting. You can look at the ACGT website (1) and get details of the multidisciplinary input; this book does not make it clear how expert sources, such as the Childhood Parent Group, participated.

The first of the two main sections, on ethical requirements, does include a useful discussion of models of consent (specified consent, blanket consent, tiered consent) and comes to a compromise model – 'intermediate scope consent'. This latter model is not too different from the approach I summarised in the third paragraph above, but obviously the authors have accompanied it with written advice, which you can examine most clearly on the ACGT website; not in the book.

The good news is that the legal requirements section does give a comprehensive analysis of the European Data Protection Directive (95/46 EC) and of the ways to apply the data protection framework, including anonymisation of genetic data within genetic research networks, expected period of usage of the consent, how to handle death of the patient and data transfer to third parties or third countries.

My own views were coloured by a fascinating five-year experience in the Sultanate of Oman, where the matter of transnational genetic research was debated not in terms of the transfer of data, but on whether any DNA should be sent out of the Sultanate to help the family by genetic testing, often in an international research laboratory which had the necessary experience. This book will not inspire the Omani academics and ethical committees to allow participation by willing Omani families in global genetic research.

My advice is that you do not waste time or money on the book. Go instead to the web addresses (below) to examine the details of ACGT and pick out the elements that interest you most.

If you prefer to read a supportive review by a research fellow from the Max Planck Institute for Comparative Public Law and International Law in Heidelberg, try 'Ethical and Legal Requirements for Transnational Genetic Research', published in the European Journal of International Law (2).


Buy Ethical and Legal Requirements of Transnational Genetic Research from Amazon UK.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

12 August 2013 - by Dr Linda Briceño Moraia, Dr Jane Kaye and Heather Griffin 
European data protection and privacy law is in a state of flux as its governing legislation is in a process of being amended to create a unified regime for data protection across Europe....
10 October 2011 - by Dr Mary Yarwood 
Plans to introduce broad powers to allow police to retain the DNA of innocent people should be abandoned, the UK Joint Committee on Human Rights (JCHR) has said....

12 August 2011 - by Anna Wade 
What happens when a research team discovers something that has direct significance to the health of an individual involved in their study? Although the discovery of 'health-related findings' can occur in any study involving human participants, the answer to this question is by no means clear....
28 March 2011 - by Dr Christine Patch and Dr Barbara Prainsack 
People interested in consumer genetics eagerly anticipated the meeting on 8-9 March 2011 of an US Food and Drug Administration (FDA) advisory panel on consumer genetics. The 21-member panel comprised academics, clinicians, a patient organisation member, a company representative, and one consumer...
21 February 2011 - by Dr Lux Fatimathas 
An article published by a group of international scientists has said an over emphasis on the Human Genome Project (HGP) may risk a 'backlash' in the field of genetics and has called for an evaluation of where the 'real benefits' from genomic medicine will come from....
26 July 2008 - by Dr Rachael Panizzo 
The philosopher Robert Nozick introduced the idea of a genetic supermarket in 1974, before the first IVF birth and the era of medical genetics. At the genetic supermarket, he imagined, prospective parents could shop for desired traits, and design a child to their particular specifications. In 'Defending the Genetic Supermarket', Colin Gavaghan explores the ethics underlying the use of assisted reproductive technologies, in particular preimplantation genetic diagnosis (PGD), as well as the cur...
26 November 2007 - by Ailsa Stevens 
Two rival companies have launched novel genetic services which, for a price tag of $1000 (£483), will allow people to have their genomes scanned, delivering them personal information about their ancestry, some personal disease risks and other inherited traits. The first - called deCODEme - was launched by Icelandic...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Moving the Boundaries of Human Reproduction

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Jacques Cohen

Dr Anna Smajdor

Dr Andy Greenfield

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation